Franziska Eckardt

Munich, BY, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Teaching ophthalmic microsurgical skills: conventional microscopy versus heads-up visualization.

Teaching ophthalmic microsurgical skills: conventional microscopy versus heads-up visualization.

Journal: BMC medical education

Published: June 15, 2026

Real-time OCT-guided strategies for optimization of precision and safety in vitreoretinal surgery

Real-time OCT-guided strategies for optimization of precision and safety in vitreoretinal surgery

Journal: Die Ophthalmologie

Published: April 13, 2026

Concepts and clinical application of digital 3D microscopy

Concepts and clinical application of digital 3D microscopy

Journal: Die Ophthalmologie

Published: January 30, 2026

Efficacy of 2 mg vs. High-Dose 8 mg Aflibercept in Neovascular Age Related Macular Degeneration.

Efficacy of 2 mg vs. High-Dose 8 mg Aflibercept in Neovascular Age Related Macular Degeneration.

Journal: Klinische Monatsblatter fur Augenheilkunde

Published: December 15, 2025

Extended Real-World Efficacy of Faricimab in Therapy-Resistant Macular Edema Due to Retinal Vein Occlusion: 9-Month Follow-Up Results.

Extended Real-World Efficacy of Faricimab in Therapy-Resistant Macular Edema Due to Retinal Vein Occlusion: 9-Month Follow-Up Results.

Journal: Journal of clinical medicine

Published: September 16, 2025

High-Dose 8 mg Aflibercept for Neovascular Age-Related Macular Degeneration: Who Is Being Treated with This New Agent?

High-Dose 8 mg Aflibercept for Neovascular Age-Related Macular Degeneration: Who Is Being Treated with This New Agent?

Journal: Life (Basel, Switzerland)

Published: September 16, 2025

Real-World Data on Morphological and Functional Responses After Switching to Faricimab in Recalcitrant, Chronic Diabetic Macular Edema.

Real-World Data on Morphological and Functional Responses After Switching to Faricimab in Recalcitrant, Chronic Diabetic Macular Edema.

Journal: Ophthalmology and therapy

Published: March 16, 2025

Switching to Faricimab in Therapy-Resistant Macular Edema Due to Retinal Vein Occlusion: Initial Real-World Efficacy Outcomes.

Switching to Faricimab in Therapy-Resistant Macular Edema Due to Retinal Vein Occlusion: Initial Real-World Efficacy Outcomes.

Journal: Journal of clinical medicine

Published: March 11, 2025

Deep learning assisted analysis of biomarker changes in refractory neovascular AMD after switch to faricimab.

Deep learning assisted analysis of biomarker changes in refractory neovascular AMD after switch to faricimab.

Journal: International journal of retina and vitreous

Published: February 20, 2025

Efficacy of switching treatment to faricimab in recalcitrant neovascular age related macular degeneration - 6 month results after completion of the loading phase.

Efficacy of switching treatment to faricimab in recalcitrant neovascular age related macular degeneration - 6 month results after completion of the loading phase.

Journal: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie

Published: February 14, 2025

Internal Limiting Membrane Peeling in Primary Rhegmatogenous Retinal Detachment: Functional and Morphologic Results.

Internal Limiting Membrane Peeling in Primary Rhegmatogenous Retinal Detachment: Functional and Morphologic Results.

Journal: Klinische Monatsblatter fur Augenheilkunde

Published: February 13, 2025

Deep learning-assisted analysis of biomarker changes after increase of dosing from aflibercept 2 mg to 8 mg in therapy-resistant neovascular age-related macular degeneration.

Deep learning-assisted analysis of biomarker changes after increase of dosing from aflibercept 2 mg to 8 mg in therapy-resistant neovascular age-related macular degeneration.

Journal: BMJ open ophthalmology

Published: February 02, 2025

Showing 1-12 of 18

Last Updated: 09/26/2026